# Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

> **NCT04506086** · PHASE4 · TERMINATED · sponsor: **Amgen** · enrollment: 10 (actual)

## Conditions studied

- B-precursor Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab
- **DEVICE:** Current Wearable Heatlth Monitoring System (CWHMS)

## Key facts

- **NCT ID:** NCT04506086
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-26
- **Primary completion:** 2024-07-04
- **Final completion:** 2024-09-16
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned.
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04506086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04506086, "Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04506086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*